目的:通过生物信息学分析,探讨结直肠癌与不同距离癌旁组织中的基因差异表达的机制。方法:通过Illumina Novaseq 6000测序平台对所选标本进行真核mRNA测序。结果:表达量差异分析显示,在结直肠癌上缘组中差异表达基因共28 000个,其中上缘差异表达上调基因11 735个,差异表达下调基因16 265个;在结直肠癌下缘组中差异表达基因共32 438个,其中差异表达上调基因11 477个,差异表达下调基因20 961个。表达量差异火山图筛选出结直肠癌组织和不同距离癌旁组织中共有的下调基因有IGF2BP1、ADAM12、CDON、AKAP6、IGSF9B、LONR2、KCNB1。差异基因功能注释分析显示,差异基因主要参与细胞过程,参与的通路主要有新陈代谢、信号转导及免疫系统等。在发病机制方面主要存在于癌症方面、神经系统疾病及胃肠系统疾病等。差异基因富集分析显示,差异基因主要在心脏传导、胶原纤维组织、胶原蛋白分解过程等,富集的通路主要为人乳头病毒感染通路及P13K-Akt信号通路等。结论:差异基因IGF2BP1、ADAM12、CDON、AKAP6、IGSF9B、LONR2、KCNB1在结直肠癌组织与不同距离癌旁组织中表达下调。差异基因存在于细胞中,主要参与新陈代谢通路、信号转导通路及免疫系统通路。发病机制方面主要存在于癌症方面、神经系统疾病及胃肠系统疾病等。
Objective: To explore the genes and mechanisms in colorectal cancer and adjacent tissues at different distances by bioinformatics analysis. Methods: Eukaryotic mRNA was sequenced by Illumina Novaseq 6000 sequencing platform. Results: Differential expression analysis showed that there were 28 000 differentially expressed genes in the upper margin group of colorectal cancer, of which 11 735 were up-regulated and 16 265 were down-regulated. There were 32 438 differentially expressed genes in the lower margin group of colorectal cancer, of which 11 477 were up-regulated and 20 961 were down-regulated. The differentially expressed genes IGF2BP1, ADAM12, CDON, AKAP6, IGSF9B, LONR2 and KCNB1 were found to be down-regulated in colorectal cancer tissues and adjacent tissues at different distances. Functional annotation analysis of differential genes showed that differential genes were mainly involved in cellular processes, and the pathways involved were mainly metabolism, signal transduction and immune system. In terms of pathogenesis, it mainly exists in cancer, nervous system diseases and gastrointestinal system diseases. Differential gene enrichment analysis showed that differential genes were mainly in cardiac conduction, collagen fiber tissue, collagen decomposition process, etc., and the enriched pathways were mainly human papillomavirus infection pathway and P13K-Akt signaling pathway. Conclusion: The expression of differential genes IGF2BP1, ADAM12, CDON, AKAP6, IGSF9 B, LONR2 and KCNB1 is down-regulated in colorectal cancer tissues and adjacent tissues at different distances. Differential genes exist in cells and are mainly involved in metabolic pathways, signal transduction pathways, and immune system pathways. The pathogenesis mainly exists in cancer, nervous system diseases and gastrointestinal system diseases.
[1] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174.
[2] Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3): 233-254.
[3] Lauby-Secretan B, Vilahur N, Bianchini F, et al. The IARC perspective on colorectal cancer screening[J]. N Engl J Med, 2018, 378(18): 1734-1740.
[4] Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death[J]. N Engl J Med, 2022, 387(17): 1547-1556.
[5] Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development[J]. N Engl J Med, 1988, 319(9): 525-532.
[6] Thanikachalam K, Khan G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164.
[7] Shinji S, Yamada T, Matsuda A, et al. Recent advances in the treatment of colorectal cancer: a review[J]. J Nippon Med Sch, 2022, 89(3): 246-254.
[8] Chakedis J, Schmidt CR. Surgical treatment of metastatic colorectal cancer[J]. Surg Oncol Clin N Am, 2018, 27(2): 377-399.
[9] Itatani Y, Kawada K, Sakai Y. Treatment of elderly patients with colorectal cancer[J]. Biomed Res Int, 2018, 2018: 2176056.
[10] Chen HM, Lin CC, Chen WS, et al. Insulin-Like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a prognostic biomarker and associated with chemotherapy responsiveness in colorectal cancer[J]. Int J Mol Sci, 2021, 22(13): 6940.
[11] Liu Y, Guo Q, Yang H, et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment[J]. ACS Cent Sci, 2022, 8(8): 1102-1115.
[12] Huang Z, Lai H, Liao J, et al. Upregulation of ADAM12 is associated with a poor survival and immune cell infiltration in colon adenocarcinoma[J]. Front Oncol, 2021, 11: 729230.
[13] Uko NE, Güner OF, Matesic DF, et al. Akt pathway inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 883-900.
[14] Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment[J]. Annu Rev Med, 2016, 67: 11-28.
[15] Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer [J]. Front Biosci (Landmark Ed), 2016, 21(5): 1084-1091.
[16] Zhu K, Wu Y, He P, et al. PI3K/AKT/mTOR-Targeted therapy for breast cancer[J]. Cells, 2022, 11(16): 2508.
[17] Zhou LA, Liu TB, Lü HN. Geraniin inhibits proliferation and induces apoptosis through inhibition of phosphatidylinositol 3-kinase/Akt pathway in human colorectal cancer in vitro and in vivo[J]. Anticancer Drugs, 2020, 31(6): 575-582.
[18] He Z, Xu Y, Rao Z, et al. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine[J]. Sci Total Environ, 2024, 912: 169604.
